## Marzena Anna Lewandowska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5918010/publications.pdf

Version: 2024-02-01

414414 331670 1,097 37 21 32 citations g-index h-index papers 38 38 38 1955 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Prognostic and Predictive Biomarkers: Tools in Personalized Oncology. Molecular Diagnosis and Therapy, 2014, 18, 273-284.	3.8	132
2	Prognostic and Predictive Biomarkers in Gliomas. International Journal of Molecular Sciences, 2021, 22, 10373.	4.1	110
3	High copy number variation of cancer-related microRNA genes and frequent amplification of <i>DICER1</i> and <i>DROSHA</i> in lung cancer. Oncotarget, 2015, 6, 23399-23416.	1.8	60
4	Prognostic and Predictive Epigenetic Biomarkers in Oncology. Molecular Diagnosis and Therapy, 2019, 23, 83-95.	3.8	57
5	Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Science Translational Medicine, 2018, 10, .	12.4	55
6	RNA structure is a key regulatory element in pathological ATM and CFTR pseudoexon inclusion events. Nucleic Acids Research, 2007, 35, 4369-4383.	14.5	53
7	U1-snRNA–mediated rescue of mRNA processing in severe factor VII deficiency. Blood, 2008, 111, 2681-2684.	1.4	53
8	The missing puzzle piece: splicing mutations. International Journal of Clinical and Experimental Pathology, 2013, 6, 2675-82.	0.5	46
9	Deletion of CFTR Translation Start Site Reveals Functional Isoforms of the Protein in CF Patients. Cellular Physiology and Biochemistry, 2009, 24, 335-346.	1.6	45
10	Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors. Molecules, 2020, 25, 1864.	3.8	45
11	A KCNH2 branch point mutation causing aberrant splicing contributes to an explanation of genotype-negative long QT syndrome. Heart Rhythm, 2009, 6, 212-218.	0.7	41
12	Somatic Mutations in miRNA Genes in Lung Cancerâ€"Potential Functional Consequences of Non-Coding Sequence Variants. Cancers, 2019, 11, 793.	3.7	37
13	Tumor suppression by collagen XV is independent of the restin domain. Matrix Biology, 2012, 31, 285-289.	3.6	32
14	KRAS and BRAF Mutation Analysis in Colorectal Adenocarcinoma Specimens with a Low Percentage of Tumor Cells. Molecular Diagnosis and Therapy, 2013, 17, 193-203.	3.8	32
15	The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology, 2015, 141, 61-68.	2.5	32
16	Molecular mechanisms controlling <i>CFTR</i> gene expression in the airway. Journal of Cellular and Molecular Medicine, 2012, 16, 1321-1330.	3.6	31
17	Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients. Oncology Reports, 2013, 30, 1045-1052.	2.6	30
18	Functional studies on the ATM intronic splicing processing element. Nucleic Acids Research, 2005, 33, 4007-4015.	14.5	23

#	Article	IF	Citations
19	An Alu-derived intronic splicing enhancer facilitates intronic processing and modulates aberrant splicing in ATM. Nucleic Acids Research, 2009, 37, 7258-7267.	14.5	23
20	Multiple Mechanisms Influence Regulation of the Cystic Fibrosis Transmembrane Conductance Regulator Gene Promoter. American Journal of Respiratory Cell and Molecular Biology, 2010, 43, 334-341.	2.9	21
21	Characterization of MRP RNA–protein interactions within the perinucleolar compartment. Molecular Biology of the Cell, 2011, 22, 858-866.	2.1	21
22	An Analysis of the Prognostic Value of IDH1 (Isocitrate Dehydrogenase 1) Mutation in Polish Glioma Patients. Molecular Diagnosis and Therapy, 2014, 18, 45-53.	3.8	21
23	The Use of a Two-Tiered Testing Strategy for the Simultaneous Detection of Small EGFR Mutations and EGFR Amplification in Lung Cancer. PLoS ONE, 2015, 10, e0117983.	2.5	16
24	The relationship between HER2 overexpression and angiogenesis in gastric cancer. Medicine (United) Tj ETQq0 C	0 0 1gBT /C	verlock 10 Tf
25	Differential gene methylation patterns in cancerous and non‑cancerous cells. Oncology Reports, 2019, 42, 43-54.	2.6	13
26	BRCA1/2 Mutation Detection in the Tumor Tissue from Selected Polish Patients with Breast Cancer Using Next Generation Sequencing. Genes, 2021, 12, 519.	2.4	13
27	Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions. International Journal of Molecular Sciences, 2016, 17, 1876.	4.1	11
28	Can chromatin conformation technologies bring light into human molecular pathology?. Acta Biochimica Polonica, 2015, 62, 483-489.	0.5	8
29	Transdifferentiation of Bone Marrow Mesenchymal Stem Cells into the Islet-Like Cells: the Role of Extracellular Matrix Proteins. Archivum Immunologiae Et Therapiae Experimentalis, 2015, 63, 377-384.	2.3	8
30	Analysis of EGFR mutation frequency and coexistence of KRAS and EGFR mutations using RT-PCR in lung adenocarcinoma: may a clinical and pathological model of a patient's qualification for targeted therapy have an impact on time to obtain genetic results?. Kardiochirurgia I Torakochirurgia Polska, 2012, 4, 443-451.	0.1	4
31	Impact of Specific KRAS Mutation in Exon 2 on Clinical Outcome of Chemotherapy- and Radiotherapy-Treated Colorectal Adenocarcinoma Patients. Molecular Diagnosis and Therapy, 2014, 18, 559-566.	3.8	3
32	Chromosome Conformation Capture Reveals Two Elements That Interact with the PTBP3 (ROD1) Transcription Start Site. International Journal of Molecular Sciences, 2019, 20, 242.	4.1	3
33	Detection of somatic mutations in ctDNA derived from adenocarcinoma patients – EGFR tyrosine kinase inhibitor monitoring preliminary study. Wspolczesna Onkologia, 2019, 23, 87-91.	1.4	2
34	Personalized medicine in oncology: vision or realistic concept?. Wspolczesna Onkologia, 2011, 1, 1-6.	1.4	1
35	EXPERIMENTAL CARDIOVASCULAR AND LUNG RESEARCH From mutation to methylation – molecular markers in lung cancer. Kardiochirurgia I Torakochirurgia Polska, 2013, 2, 148-153.	0.1	0
36	Personalized and targeted therapies. ChemistrySelect, 2023, 8, 2103-2126.	1.5	0

#	Article	IF	CITATIONS
37	Mutation analysis in colorectal adenocarcinoma specimens to targeted treatment Journal of Clinical Oncology, 2014, 32, e14639-e14639.	1.6	O